Understanding Hypereosinophilic Syndrome
At a Glance
Hypereosinophilic Syndrome (HES) is a highly treatable rare condition characterized by a persistently high eosinophil count that can damage healthy organs. Diagnosis requires an eosinophil count over 1,500, and treatments often utilize precision genetic medicine to stop disease progression.
Hearing the term Hypereosinophilic Syndrome (HES) can be overwhelming, especially since it is a rare condition. However, modern medicine has established clear diagnostic criteria and highly effective treatments. Unlike a temporary allergic reaction, HES is a chronic condition where the body produces too many eosinophils—a type of white blood cell meant to fight parasites—which then begin to collect in and damage healthy organs [1][2].
Defining HES
To be diagnosed with HES, doctors look for two specific criteria:
- High Eosinophil Count: An Absolute Eosinophil Count (AEC) of 1,500 cells per microliter (often written on reports as
) or higher, documented on at least two occasions at least one month apart [3]. - Organ Involvement: Evidence that these cells are causing end-organ damage, meaning they are disrupting the normal function of systems like your heart, skin, lungs, digestive tract, or nervous system [4][5].
Stabilizing Facts for the Newly Diagnosed
While HES is a serious diagnosis, several facts can provide a sense of stability:
- It is highly treatable: Modern therapies, including precision medicine (drugs that target specific genetic markers) and monoclonal antibodies, have transformed HES from a poorly understood disease into a manageable one [1][6].
- Genetic testing provides a roadmap: Identifying specific genetic mutations, such as the FIP1L1-PDGFRA fusion gene, allows doctors to select “smart” drugs like imatinib that can lead to rapid and long-lasting remission [6][7].
- Rapid intervention protects organs: Once a diagnosis is made, treatments designed to quickly reduce your eosinophil count can stop the progression of tissue damage [8][9].
Incidence and Finding the Right Care
HES is considered a rare disease. While historical data often suggested it was more common in men, recent real-world studies indicate that HES may actually be more prevalent in women [10]. Because it is rare, a community allergist or oncologist may only see one case in their entire career. It is highly recommended to consult an academic medical center or a multidisciplinary team (MDT) to oversee your care.
HES vs. Common Allergies
It is common to confuse HES with severe allergies because both involve eosinophils. However, there are fundamental differences:
- Persistence: Allergic eosinophilia usually goes away once the trigger (like pollen or a specific food) is removed. In HES, the elevation is persistent and often occurs without a clear external trigger [11][5].
- Organ Damage: While allergies might cause itchy eyes or a runny nose, HES involves deeper tissue infiltration that can lead to scarring or dysfunction in major organs like the heart or liver [8][12].
- The Diagnostic Path: Diagnosis of HES requires the strict exclusion of secondary causes, such as infections or typical allergic disorders, to ensure the high cell count is truly coming from the HES process itself [13][14].
Common questions in this guide
What is the difference between HES and a normal allergic reaction?
How is Hypereosinophilic Syndrome diagnosed?
Why is genetic testing important for an HES diagnosis?
What kind of doctor treats Hypereosinophilic Syndrome?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What is my current Absolute Eosinophil Count (AEC), and how has it changed since my first test?
- 2.Have you performed genetic testing for the FIP1L1-PDGFRA mutation or other clonal markers?
- 3.What specific evidence of organ damage (heart, nerves, skin, or gut) have you found?
- 4.Which subtype of HES do I have: myeloproliferative, lymphocytic, or idiopathic?
- 5.What is our immediate plan to lower my eosinophil count and prevent further tissue damage?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (14)
- 1
Hypereosinophilic syndrome: approach to treatment in the era of precision medicine.
Klion A
Hematology. American Society of Hematology. Education Program 2018; (2018(1)):326-331 doi:10.1182/asheducation-2018.1.326.
PMID: 30504328 - 2
Clinical Profile and Treatment in Hypereosinophilic Syndrome Variants: A Pragmatic Review.
Requena G, van den Bosch J, Akuthota P, et al.
The journal of allergy and clinical immunology. In practice 2022; (10(8)):2125-2134 doi:10.1016/j.jaip.2022.03.034.
PMID: 35470096 - 3
Hypereosinophilic syndrome.
Noh HR, Magpantay GG
Allergy and asthma proceedings 2017; (38(1)):78-81 doi:10.2500/aap.2017.38.3995.
PMID: 28052805 - 4
Clinical Management of Persistent Hypereosinophilia.
Helbig G, Czachor K
European journal of haematology 2025; (114(5)):763-774 doi:10.1111/ejh.14396.
PMID: 39961601 - 5
Hypereosinophilic syndrome associated with multiple thromboses requiring ICU admission: A case report.
Ouanes I, Toumi S, Ben Cheikh Y, et al.
La Tunisie medicale 2023; (101(10)):783-786.
PMID: 38465762 - 6
FIP1L1-PDGFRA-Associated Hypereosinophilic Syndrome as a Treatable Cause of Watershed Infarction.
Tennenbaum J, Groh M, Venditti L, et al.
Stroke 2021; (52(10)):e605-e609 doi:10.1161/STROKEAHA.121.034191.
PMID: 34304603 - 7
Clinical features predict responsiveness to imatinib in platelet-derived growth factor receptor-alpha-negative hypereosinophilic syndrome.
Khoury P, Desmond R, Pabon A, et al.
Allergy 2016; (71(6)):803-10 doi:10.1111/all.12843.
PMID: 26797802 - 8
Medical algorithm: Diagnosis and treatment of hypereosinophilic syndrome.
Schuster B, Zink A, Eyerich K
Allergy 2020; (75(11)):3003-3006 doi:10.1111/all.14368.
PMID: 32416612 - 9
Hypereosinophilic Syndrome.
Curtis C, Ogbogu P
Clinical reviews in allergy & immunology 2016; (50(2)):240-51 doi:10.1007/s12016-015-8506-7.
PMID: 26475367 - 10
The increasing incidence and prevalence of hypereosinophilic syndrome in the United Kingdom.
Requena G, Logie J, Gibbons DC, et al.
Immunity, inflammation and disease 2021; (9(4)):1447-1451 doi:10.1002/iid3.495.
PMID: 34293251 - 11
Idiopathic Hypereosinophilic Syndrome Presenting with Recalcitrant Oral and Genital Ulcers Responding Well to Thalidomide.
Srinivas SM, Chebbi PG, Shivappa SK
Indian dermatology online journal 2023; (14(5)):676-678 doi:10.4103/idoj.idoj_632_22.
PMID: 37727572 - 12
An 85-Year-Old Man with Fever, Dyspnea, and Dry Cough Diagnosed with Idiopathic Hypereosinophilic Syndrome, Successfully Treated with High-Dose Corticosteroids.
Goyal P, Chhabra ST, Tandon R, et al.
The American journal of case reports 2023; (24()):e941241 doi:10.12659/AJCR.941241.
PMID: 38073150 - 13
Hypereosinophilic syndrome: a rare cause of ST-elevation myocardial infarction and thrombus formation on the aortic valve.
Jørgensen MD, Schneider IR, Thomsen GN, Dahl JS
BMJ case reports 2024; (17(4)) doi:10.1136/bcr-2023-259494.
PMID: 38627047 - 14
[Hypereosinophilic syndrome, case report and diagnostic approach].
Medina-Marroquín R, Espejel-Guzman JA, Maldonado-López CJ, Calzada-Rascón AC
Revista medica del Instituto Mexicano del Seguro Social 2024; (62(2)):1-6.
PMID: 39514634
This page provides educational information about Hypereosinophilic Syndrome (HES) and its diagnostic criteria. It does not replace professional medical advice. Always consult your healthcare team for diagnosis and treatment planning.
Get notified when new evidence is published on Hypereosinophilic syndrome.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.